Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: Xenofon Baraliakos Clear advanced filters

  • Imaging is central for the classification and diagnosis of axial spondyloarthritis, as well as for monitoring disease progression and predicting response to treatment. Xenofon Baraliakos and Jürgen Braun provide an overview of the role of imaging for patients with axial spondyloarthritis and discuss how imaging techniques might influence research and clinical practice in the future.

    • Xenofon Baraliakos
    • Jürgen Braun
    Reviews
    Nature Reviews Rheumatology
    Volume: 9, P: 498-502

  • Although current treatments for axial spondyloarthritis can reduce inflammation, many patients continue to experience pain. This Review examines the complex interplay between pain and inflammation in axial spondyloarthritis and argues that both should be addressed as interconnected therapeutic targets to achieve meaningful pain relief.

    • Xenofon Baraliakos
    • Victoria Navarro-Compán
    • Denis Poddubnyy
    Reviews
    Nature Reviews Rheumatology
    P: 1-14

  • Biologic DMARDs are a cornerstone treatment for severe axial spondyloarthritis. Although indications for treatment initiation are well codified, the timing and modalities for tapering remain unclear, despite medical and economic concerns. Encouraging data about treatment tapering are emerging that might guide future management strategies.

    • Nelly R. Ziade
    • Xenofon Baraliakos
    News & Views
    Nature Reviews Rheumatology
    Volume: 15, P: 322-324

  • Biomarkers and surrogate outcome measures can be used to monitor disease development, but what can biomarkers tell us about disease processes in axial spondyloarthritis? New research suggests that some biomarkers might be useful in monitoring patients with ankylosing spondylitis, but greater understanding of the pathological mechanisms is needed.

    • Jürgen Braun
    • Xenofon Baraliakos
    News & Views
    Nature Reviews Rheumatology
    Volume: 8, P: 8-10

  • NSAIDs are first line therapy for patients with axial spondyloarthritis and are recommended to be taken continuously in patients with active disease, but their ability to affect radiographic disease progression has been uncertain. Does a new meta-analysis shed light on this matter, or is it too soon to tell?

    • Jürgen Braun
    • Xenofon Baraliakos
    News & Views
    Nature Reviews Rheumatology
    Volume: 16, P: 9-10

  • Physical function is an important contributor towards a patient’s quality of life, but is often neglected in management strategies for axial spondyloarthritis (axSpA). This Review provides guidance on determinants and assessments of physical function in axSpA.

    • Jürgen Braun
    • Xenofon Baraliakos
    • Uta Kiltz
    Reviews
    Nature Reviews Rheumatology
    Volume: 17, P: 565-576